MD (Pediatrix Medical Group, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | Laura A Linynsky | Director | D | — | — |
| 2026-08-18 | Sylvia Jean Young | Director | D | — | — |
| 2026-08-14 | Laura A Linynsky | Director | A | — | — |
| 2026-08-14 | Michael A. Rucker | Director | A | — | — |
| 2026-08-14 | Sylvia Jean Young | Director | A | — | — |
| 2026-08-14 | Kurt Douglas Newman | Director | A | — | — |
| 2026-08-14 | GUY P SANSONE | Director | A | — | — |
| 2026-08-14 | Shirley A Weis | Director | A | — | — |
| 2026-08-14 | Thomas McEachin | Director | A | — | — |
| 2026-08-14 | John M. Starcher Jr. | Director | A | — | — |
| 2026-06-24 | David Haddock | EVP, GC & Corp Sec | A | — | — |
| 2026-06-10 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | G | — | — |
| 2026-06-03 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | F | — | — |
| 2026-06-03 | Kasandra H Rossi | EVP, CFO and Treasurer | MIXED | — | — |
| 2026-06-03 | MARK S ORDAN | Chief Executive Officer | MIXED | — | — |
| 2026-06-03 | Don Gregory Neeb | EVP, Chief Invest & Strategy | MIXED | — | — |
| 2026-05-14 | Shirley A Weis | Director | Sell | — | — |
| 2026-05-14 | Thomas McEachin | Director | G | — | — |
| 2026-05-13 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | G | — | — |
| 2026-05-11 | GUY P SANSONE | Director | A | — | — |
| 2026-05-11 | Shirley A Weis | Director | A | — | — |
| 2026-05-11 | John M. Starcher Jr. | Director | A | — | — |
| 2026-05-11 | Sylvia Jean Young | Director | A | — | — |
| 2026-05-11 | Thomas McEachin | Director | A | — | — |
| 2026-05-11 | Michael A. Rucker | Director | A | — | — |
| 2026-05-11 | Kurt Douglas Newman | Director | A | — | — |
| 2026-05-11 | Laura A Linynsky | Director | A | — | — |
| 2026-03-03 | Kasandra H Rossi | EVP, CFO and Treasurer | F | — | — |
| 2026-03-03 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | MIXED | — | — |
| 2025-12-17 | MARK S ORDAN | Chief Executive Officer | Sell | — | — |
| 2025-11-19 | Michael A. Rucker | Director | Sell | — | — |
| 2025-11-10 | Laura A Linynsky | Director | Sell | — | — |
| 2025-08-21 | Thomas McEachin | Director | G | — | — |
| 2025-08-05 | Kurt Douglas Newman | Director | A | — | — |
| 2025-08-05 | Don Gregory Neeb | EVP, Chief Invest & Strategy | A | — | — |
| 2025-06-12 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | G | — | — |
| 2025-06-03 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | MIXED | — | — |
| 2025-06-03 | MARK S ORDAN | Chief Executive Officer | A | — | — |
| 2025-06-03 | Kasandra H Rossi | EVP, CFO and Treasurer | MIXED | — | — |
| 2025-05-27 | Shirley A Weis | Director | G | — | — |
| 2025-05-12 | Sylvia Jean Young | Director | A | — | — |
| 2025-05-12 | Thomas McEachin | Director | A | — | — |
| 2025-05-12 | Michael A. Rucker | Director | A | — | — |
| 2025-05-12 | John M. Starcher Jr. | Director | A | — | — |
| 2025-05-12 | GUY P SANSONE | Director | A | — | — |
| 2025-05-12 | Shirley A Weis | Director | A | — | — |
| 2025-05-12 | MARK S ORDAN | Chief Executive Officer | F | — | — |
| 2025-05-12 | Laura A Linynsky | Director | A | — | — |
| 2025-03-07 | Mary Ann E Moore | EVP, GC, Chief Admin Off & Sec | G | — | — |
| 2025-03-04 | Kasandra H Rossi | EVP, CFO and Treasurer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 748,890 | — |
| — | Director | 605,005 | — |
| — | President | 414,687 | — |
| — | Chief Executive Officer | 410,884 | — |
| — | EVP, Chief Financial Officer | 192,785 | — |
| — | EVP, GC, Chief Admin Off & Sec | 189,890 | — |
| — | EVP, General Counsel and Secy | 189,440 | — |
| — | Chief Executive Officer | 170,001 | — |
| — | EVP, Chief Invest & Strategy | 145,234 | — |
| — | EVP, Chief Operating Officer | 143,055 | — |
| — | Director | 129,198 | — |
| — | Chief Operating Officer | 123,032 | — |
| — | EVP, Natl & Market Operations | 118,094 | — |
| — | Pres., PDX & OBX Medical Group | 109,457 | — |
| — | President, Eastern Division | 105,932 | — |
| — | EVP, CFO and Treasurer | 105,100 | — |
| — | Chief Financial Officer | 100,590 | — |
| — | Principal Accounting Officer | 96,666 | — |
| — | Director | 87,416 | — |
| — | SVP, General Counsel and Secy. | 86,594 | — |
| — | Former Chief Financial Officer | 78,027 | — |
| — | Director | 73,741 | — |
| — | Director | 73,732 | — |
| — | EVP Chf Strategy & Growth Offi | 71,954 | — |
| — | Director | 66,769 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MD quote page; the site-wide leaderboard is on the insider transactions hub.